{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:42:11Z","timestamp":1770043331349,"version":"3.49.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-029017"],"award-info":[{"award-number":["POCI-01-0145-FEDER-029017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-016390"],"award-info":[{"award-number":["POCI-01-0145-FEDER-016390"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/146186\/2019"],"award-info":[{"award-number":["SFRH\/BD\/146186\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Colorectal cancer (CRC) remains a serious health concern worldwide. Despite advances in diagnosis and treatment, about 15 to 30% of stage II CRC patients subjected to tumor resection with curative intent, develop disease relapse. Moreover, the therapeutic strategy adopted after surgery is not consensual for these patients. This supports the imperative need to find new prognostic and predictive biomarkers for stage II CRC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>For this purpose, we used a one-hospital series of 227 stage II CRC patient samples to assess the biomarker potential of the immunohistochemical expression of MUC2 mucin and CDX2 and SOX2 transcription factors. The Kaplan-Meier method was used to generate disease-free survival curves that were compared using the log-rank test, in order to determine prognosis of cases with different expression of these proteins, different mismatch repair (MMR) status and administration or not of adjuvant chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In this stage II CRC series, none of the studied biomarkers showed prognostic value for patient outcome. However low expression of MUC2, in cases with high expression of CDX2, absence of SOX2 or MMR-proficiency, conferred a significantly worst prognosis. Moreover, cases with low expression of MUC2 showed a significantly clear benefit from treatment with adjuvant chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, we observe that patients with stage II CRC with low expression of MUC2 in the tumor respond better when treated with adjuvant chemotherapy. This observation supports that MUC2 is involved in resistance to fluorouracil-based adjuvant chemotherapy and might be a promising future predictive biomarker in stage II CRC patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08070-6","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T19:03:01Z","timestamp":1617735781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Sara","family":"Ribeirinho-Soares","sequence":"first","affiliation":[]},{"given":"Diana","family":"P\u00e1dua","sequence":"additional","affiliation":[]},{"given":"Ana Lu\u00edsa","family":"Amaral","sequence":"additional","affiliation":[]},{"given":"Elvia","family":"Valentini","sequence":"additional","affiliation":[]},{"given":"Daniela","family":"Azevedo","sequence":"additional","affiliation":[]},{"given":"Cristiana","family":"Marques","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Barros","sequence":"additional","affiliation":[]},{"given":"Filipa","family":"Macedo","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Mesquita","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-1633","authenticated-orcid":false,"given":"Raquel","family":"Almeida","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"issue":"6","key":"8070_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"8070_CR2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi\u00f1eros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941\u201353. https:\/\/doi.org\/10.1002\/ijc.31937.","journal-title":"Int J Cancer"},{"issue":"19","key":"8070_CR3","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/jnci\/djh275","volume":"96","author":"JB O\u2019Connell","year":"2004","unstructured":"O\u2019Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new american joint committee on cancer sixth edition staging. JNCI J Natl Cancer Inst. 2004;96(19):1420\u20135. https:\/\/doi.org\/10.1093\/jnci\/djh275.","journal-title":"JNCI J Natl Cancer Inst."},{"issue":"4","key":"8070_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrclinonc.2016.171","volume":"14","author":"CJA Punt","year":"2017","unstructured":"Punt CJA, Koopman M, Vermeulen L. From tumor heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14(4):235\u201346. https:\/\/doi.org\/10.1038\/nrclinonc.2016.171.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"8070_CR5","doi-asserted-by":"publisher","first-page":"15065","DOI":"10.1038\/nrdp.2015.65","volume":"1","author":"EJ Kuipers","year":"2015","unstructured":"Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Prim. 2015;1(1):15065. https:\/\/doi.org\/10.1038\/nrdp.2015.65.","journal-title":"Nat Rev Dis Prim"},{"issue":"16","key":"8070_CR6","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1200\/JCO.2014.60.0213","volume":"33","author":"R Dienstmann","year":"2015","unstructured":"Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 2015;33(16):1787\u201396. https:\/\/doi.org\/10.1200\/JCO.2014.60.0213.","journal-title":"J Clin Oncol"},{"issue":"25","key":"8070_CR7","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO.2010.34.3426","volume":"29","author":"ES O\u2019Connor","year":"2011","unstructured":"O\u2019Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29(25):3381\u20138. https:\/\/doi.org\/10.1200\/JCO.2010.34.3426.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8070_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1200\/JOP.2016.017210","volume":"13","author":"J Kannarkatt","year":"2017","unstructured":"Kannarkatt J, Joseph J, Kurniali PC, Al-Janadi A, Hrinczenko B. Adjuvant chemotherapy for stage II colon cancer: a clinical dilemma. J Oncol Pract. 2017;13(4):233\u201341. https:\/\/doi.org\/10.1200\/JOP.2016.017210.","journal-title":"J Oncol Pract"},{"issue":"Suppl 6","key":"8070_CR9","doi-asserted-by":"publisher","first-page":"vi64","DOI":"10.1093\/annonc\/mdt354","volume":"24","author":"R Labianca","year":"2013","unstructured":"Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(Suppl 6):vi64\u201372. https:\/\/doi.org\/10.1093\/annonc\/mdt354.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"6","key":"8070_CR10","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.cell.2013.02.014","volume":"152","author":"TI Lee","year":"2013","unstructured":"Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013;152(6):1237\u201351. https:\/\/doi.org\/10.1016\/j.cell.2013.02.014.","journal-title":"Cell."},{"issue":"1","key":"8070_CR11","doi-asserted-by":"publisher","first-page":"39709","DOI":"10.1038\/srep39709","volume":"6","author":"MM Falco","year":"2016","unstructured":"Falco MM, Bleda M, Carbonell-Caballero J, Dopazo J. The pan-cancer pathological regulatory landscape. Sci Rep. 2016;6(1):39709. https:\/\/doi.org\/10.1038\/srep39709.","journal-title":"Sci Rep"},{"issue":"3","key":"8070_CR12","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1158\/0008-5472.CAN-17-1679","volume":"78","author":"L Garcia-Alonso","year":"2018","unstructured":"Garcia-Alonso L, Iorio F, Matchan A, Fonseca N, Jaaks P, Peat G, et al. Transcription factor activities enhance markers of drug sensitivity in Cancer. Cancer Res. 2018;78(3):769\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1679.","journal-title":"Cancer Res"},{"issue":"4","key":"8070_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1053\/gast.2000.18142","volume":"119","author":"DG Silberg","year":"2000","unstructured":"Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and cdx2 expression during intestinal development. Gastroenterology. 2000;119(4):961\u201371. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11040183. Accessed 26 July 2018. https:\/\/doi.org\/10.1053\/gast.2000.18142.","journal-title":"Gastroenterology."},{"issue":"3","key":"8070_CR14","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.3892\/mmr.2015.3838","volume":"12","author":"ZHENG J-B","year":"2015","unstructured":"J-B ZHENG, L-N QIAO, X-J SUN, et al. Overexpression of caudal-related homeobox transcription factor 2 inhibits the growth of transplanted colorectal tumors in nude mice. Mol Med Rep. 2015;12(3):3409\u201315. https:\/\/doi.org\/10.3892\/mmr.2015.3838.","journal-title":"Mol Med Rep"},{"issue":"1","key":"8070_CR15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/s12885-016-2509-5","volume":"16","author":"IV Lundberg","year":"2016","unstructured":"Lundberg IV, Edin S, Ekl\u00f6f V, \u00d6berg \u00c5, Palmqvist R, Wikberg ML. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer. BMC Cancer. 2016;16(1):471. https:\/\/doi.org\/10.1186\/s12885-016-2509-5.","journal-title":"BMC Cancer"},{"issue":"3","key":"8070_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1506597","volume":"374","author":"P Dalerba","year":"2016","unstructured":"Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, et al. CDX2 as a prognostic biomarker in stage II and stage III Colon Cancer. N Engl J Med. 2016;374(3):211\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1506597.","journal-title":"N Engl J Med"},{"issue":"5","key":"8070_CR17","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3748\/wjg.v21.i5.1457","volume":"21","author":"JM Bae","year":"2015","unstructured":"Bae JM, Lee TH, Cho N-Y, Kim T-Y, Kang GH. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World J Gastroenterol. 2015;21(5):1457\u201367. https:\/\/doi.org\/10.3748\/wjg.v21.i5.1457.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"8070_CR18","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/1878-0261.12347","volume":"12","author":"J Bruun","year":"2018","unstructured":"Bruun J, Sveen A, Barros R, Eide PW, Eilertsen I, Kolberg M, et al. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Mol Oncol. 2018;12(9):1639\u201355. https:\/\/doi.org\/10.1002\/1878-0261.12347.","journal-title":"Mol Oncol"},{"issue":"51","key":"8070_CR19","doi-asserted-by":"publisher","first-page":"51549","DOI":"10.1074\/jbc.M309019200","volume":"278","author":"P Mesquita","year":"2003","unstructured":"Mesquita P, Jonckheere N, Almeida R, Ducourouble MP, Serpa J, Silva E, et al. Human MUC2 Mucin gene is transcriptionally regulated by cdx Homeodomain proteins in gastrointestinal carcinoma cell lines. J Biol Chem. 2003;278(51):51549\u201356. https:\/\/doi.org\/10.1074\/jbc.M309019200.","journal-title":"J Biol Chem"},{"issue":"3","key":"8070_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1245\/s10434-010-1338-z","volume":"18","author":"H Kang","year":"2011","unstructured":"Kang H, Min BS, Lee KY, Kim NK, Kim SN, Choi J, et al. Loss of E-cadherin and MUC2 expressions correlated with poor survival in patients with stages II and III colorectal carcinoma. Ann Surg Oncol. 2011;18(3):711\u20139. https:\/\/doi.org\/10.1245\/s10434-010-1338-z.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"8070_CR21","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/ijc.26182","volume":"130","author":"L Ohlsson","year":"2012","unstructured":"Ohlsson L, Israelsson A, \u00d6berg \u00c5, Palmqvist R, Stenlund H, Hammarstr\u00f6m ML, et al. Lymph node CEA and MUC2 mRNA as useful predictors of outcome in colorectal cancer. Int J Cancer. 2012;130(8):1833\u201343. https:\/\/doi.org\/10.1002\/ijc.26182.","journal-title":"Int J Cancer"},{"issue":"2","key":"8070_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s13277-012-0588-8","volume":"34","author":"A Elzagheid","year":"2013","unstructured":"Elzagheid A, Emaetig F, Buhmeida A, Laato M, el-Faitori O, Syrj\u00e4nen K, et al. Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma. Tumor Biol. 2013;34(2):621\u20138. https:\/\/doi.org\/10.1007\/s13277-012-0588-8.","journal-title":"Tumor Biol"},{"issue":"3","key":"8070_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00428-016-1970-5","volume":"469","author":"J Betge","year":"2016","unstructured":"Betge J, Schneider NI, Harbaum L, Pollheimer MJ, Lindtner RA, Kornprat P, et al. MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. Virchows Arch. 2016;469(3):255\u201365. https:\/\/doi.org\/10.1007\/s00428-016-1970-5.","journal-title":"Virchows Arch"},{"key":"8070_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.humpath.2019.05.005","volume":"90","author":"MJ Cecchini","year":"2019","unstructured":"Cecchini MJ, Walsh JC, Parfitt J, Chakrabarti S, Correa RJ, MacKenzie MJ, et al. CDX2 and Muc2 IHC as prognostic markers in stage II colon cancer. Hum Pathol. 2019;90:70\u20139. https:\/\/doi.org\/10.1016\/j.humpath.2019.05.005.","journal-title":"Hum Pathol"},{"issue":"1","key":"8070_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1146\/annurev.ph.57.030195.003135","volume":"57","author":"SJ Gendler","year":"1995","unstructured":"Gendler SJ, Spicer AP. Epithelial Mucin genes. Annu Rev Physiol. 1995;57(1):607\u201334. https:\/\/doi.org\/10.1146\/annurev.ph.57.030195.003135.","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"8070_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ijc.2910590302","volume":"59","author":"M Blank","year":"1994","unstructured":"Blank M, Klussmann E, Kr\u00fcger-Krasagakes S, Schmitt-Gr\u00e4ff A, Stolte M, Bornhoeft G, et al. Expression of MUC2-mucin in colorectal adenomas and carcinomas of different histological types. Int J Cancer. 1994;59(3):301\u20136. https:\/\/doi.org\/10.1002\/ijc.2910590302.","journal-title":"Int J Cancer"},{"issue":"7","key":"8070_CR27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1357-2725(98)00028-4","volume":"30","author":"A Allen","year":"1998","unstructured":"Allen A, Hutton DA, Pearson JP. The MUC2 gene product: a human intestinal mucin. Int J Biochem Cell Biol. 1998;30(7):797\u2013801. https:\/\/doi.org\/10.1016\/S1357-2725(98)00028-4.","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"8070_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/path.951","volume":"195","author":"PA Sylvester","year":"2001","unstructured":"Sylvester PA, Myerscough N, Warren BF, Carlstedt I, Corfield AP, Durdey P, et al. Differential expression of the chromosome 11 mucin genes in colorectal cancer. J Pathol. 2001;195(3):327\u201335. https:\/\/doi.org\/10.1002\/path.951.","journal-title":"J Pathol"},{"issue":"1\u20132","key":"8070_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/A:1025815113599","volume":"23","author":"JC Byrd","year":"2004","unstructured":"Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004;23(1\u20132):77\u201399. https:\/\/doi.org\/10.1023\/A:1025815113599.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"8070_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.stem.2012.12.007","volume":"12","author":"A Sarkar","year":"2013","unstructured":"Sarkar A, Hochedlinger K. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell. 2013;12(1):15\u201330. https:\/\/doi.org\/10.1016\/j.stem.2012.12.007.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"8070_CR31","doi-asserted-by":"publisher","first-page":"e101957","DOI":"10.1371\/journal.pone.0101957","volume":"9","author":"IV Lundberg","year":"2014","unstructured":"Lundberg IV, L\u00f6fgren Burstr\u00f6m A, Edin S, et al. SOX2 expression is regulated by braf and contributes to poor patient prognosis in colorectal cancer. PLoS One. 2014;9(7):e101957. https:\/\/doi.org\/10.1371\/journal.pone.0101957.","journal-title":"PLoS One"},{"issue":"3","key":"8070_CR32","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11596-016-1584-9","volume":"36","author":"X Du","year":"2016","unstructured":"Du X, Wang L, Chen X, Li Y, Li Y, Cao Y. Prognostic value of Sox2 expression in digestive tract cancers: a meta-analysis. J Huazhong Univ Sci Technol [Medical Sci]. 2016;36(3):305\u201312. https:\/\/doi.org\/10.1007\/s11596-016-1584-9.","journal-title":"J Huazhong Univ Sci Technol [Medical Sci]"},{"issue":"1","key":"8070_CR33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1186\/1471-2407-14-753","volume":"14","author":"V Camilo","year":"2014","unstructured":"Camilo V, Barros R, Celestino R, Castro P, Vieira J, Teixeira MR, et al. Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome. BMC Cancer. 2014;14(1):753. https:\/\/doi.org\/10.1186\/1471-2407-14-753.","journal-title":"BMC Cancer"},{"issue":"2","key":"8070_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","volume":"100","author":"M Koopman","year":"2009","unstructured":"Koopman M, Kortman GAM, Mekenkamp L, Ligtenberg MJL, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266\u201373. https:\/\/doi.org\/10.1038\/sj.bjc.6604867.","journal-title":"Br J Cancer"},{"issue":"16","key":"8070_CR35","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/jnci\/dji237","volume":"97","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). JNCI J Natl Cancer Inst. 2005;97(16):1180\u20134. https:\/\/doi.org\/10.1093\/jnci\/dji237.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"3","key":"8070_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrclinonc.2009.237","volume":"7","author":"E Vilar","year":"2010","unstructured":"Vilar E, Gruber SB. Microsatellite instability in colorectal cancer the stable evidence. Nat Rev Clin Oncol. 2010;7(3):153\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2009.237.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"8070_CR37","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.clcc.2016.11.001","volume":"16","author":"AK Alex","year":"2017","unstructured":"Alex AK, Siqueira S, Coudry R, Santos J, Alves M, Hoff PM, et al. Response to chemotherapy and prognosis in metastatic colorectal Cancer with DNA deficient mismatch repair. Clin Colorectal Cancer. 2017;16(3):228\u201339. https:\/\/doi.org\/10.1016\/j.clcc.2016.11.001.","journal-title":"Clin Colorectal Cancer"},{"issue":"14","key":"8070_CR38","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1158\/1078-0432.CCR-09-0401","volume":"15","author":"Y Baba","year":"2009","unstructured":"Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, et al. Relationship of CDX2 loss with molecular features and prognosis in colorectal Cancer. Clin Cancer Res. 2009;15(14):4665\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0401.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"8070_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.clcc.2016.09.003","volume":"16","author":"BY Zhang","year":"2017","unstructured":"Zhang BY, Jones JC, Briggler AM, Hubbard JM, Kipp BR, Sargent DJ, et al. Lack of caudal-type homeobox transcription factor 2 expression as a prognostic biomarker in metastatic colorectal cancer. Clin Colorectal Cancer. 2017;16(2):124\u20138. https:\/\/doi.org\/10.1016\/j.clcc.2016.09.003.","journal-title":"Clin Colorectal Cancer"},{"issue":"9","key":"8070_CR40","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.14670\/HH-23.1043","volume":"23","author":"S Bakaris","year":"2008","unstructured":"Bakaris S, Cetinkaya A, Ezberci F, Ekerbicer H. Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma. Histol Histopathol. 2008;23(9):1043\u20137. https:\/\/doi.org\/10.14670\/HH-23.1043.","journal-title":"Histol Histopathol"},{"issue":"10","key":"8070_CR41","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/ijc.28564","volume":"134","author":"H Dawson","year":"2014","unstructured":"Dawson H, Galv\u00e1n JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, et al. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer. 2014;134(10):2342\u201351. https:\/\/doi.org\/10.1002\/ijc.28564.","journal-title":"Int J Cancer"},{"issue":"1","key":"8070_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/J.YEXMP.2015.11.009","volume":"100","author":"J Olsen","year":"2016","unstructured":"Olsen J, Eiholm S, Kirkeby LT, Espersen MLM, Jess P, G\u00f6gen\u00fcr I, et al. CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer. Exp Mol Pathol. 2016;100(1):59\u201366. https:\/\/doi.org\/10.1016\/J.YEXMP.2015.11.009.","journal-title":"Exp Mol Pathol"},{"issue":"11","key":"8070_CR43","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.1128\/mcb.14.11.7340","volume":"14","author":"E Suh","year":"1994","unstructured":"Suh E, Chen L, Taylor J, Traber PG. A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol Cell Biol. 1994;14(11):7340\u201351. https:\/\/doi.org\/10.1128\/mcb.14.11.7340.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"8070_CR44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1128\/mcb.16.2.619","volume":"16","author":"E Suh","year":"1996","unstructured":"Suh E, Traber PG. An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol. 1996;16(2):619\u201325. https:\/\/doi.org\/10.1128\/mcb.16.2.619.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"8070_CR45","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/PAS.0000000000001356","volume":"43","author":"K Slik","year":"2019","unstructured":"Slik K, Turkki R, Carp\u00e9n O, Kurki S, Korkeila E, Sundstr\u00f6m J, et al. CDX2 loss with microsatellite stable phenotype predicts poor clinical outcome in stage II colorectal carcinoma. Am J Surg Pathol. 2019;43(11):1473\u201382. https:\/\/doi.org\/10.1097\/PAS.0000000000001356.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"8070_CR46","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/bjs5.91","volume":"2","author":"\u00c9J Ryan","year":"2018","unstructured":"Ryan \u00c9J, Creavin B, Khaw YL, Kelly ME, Mohan HM, Geraghty R, et al. Effects of CDX2 on prognosis and chemotherapy responsiveness in mismatch repair-deficient colorectal cancer. BJS Open. 2018;2(6):456\u201363. https:\/\/doi.org\/10.1002\/bjs5.91.","journal-title":"BJS Open"},{"issue":"22","key":"8070_CR47","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1056\/NEJMc1602584#SA2","volume":"374","author":"M Schirripa","year":"2016","unstructured":"Schirripa M, Loupakis F, Lenz H-J. CDX2 as a prognostic biomarker in Colon Cancer. N Engl J Med. 2016;374(22):2183. https:\/\/doi.org\/10.1056\/NEJMc1602584#SA2.","journal-title":"N Engl J Med"},{"issue":"11","key":"8070_CR48","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s41416-018-0285-5","volume":"119","author":"TF Hansen","year":"2018","unstructured":"Hansen TF, Kj\u00e6r-Frifeldt S, Eriksen AC, Lindebjerg J, Jensen LH, S\u00f8rensen FB, et al. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. Br J Cancer. 2018;119(11):1367\u201373. https:\/\/doi.org\/10.1038\/s41416-018-0285-5.","journal-title":"Br J Cancer"},{"issue":"12","key":"8070_CR49","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3390\/cancers11121891","volume":"11","author":"A Nishiuchi","year":"2019","unstructured":"Nishiuchi A, Hisamori S, Sakaguchi M, Fukuyama K, Hoshino N, Itatani Y, et al. MicroRNA-9-5p-CDX2 Axis: a useful prognostic biomarker for patients with stage II\/III colorectal Cancer. Cancers (Basel). 2019;11(12):1891. https:\/\/doi.org\/10.3390\/cancers11121891.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"8070_CR50","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/jcp.2006.039552","volume":"60","author":"A Lugli","year":"2007","unstructured":"Lugli A, Zlobec I, Baker K, Minoo P, Tornillo L, Terracciano L, et al. Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status. J Clin Pathol. 2007;60(5):534\u20139. https:\/\/doi.org\/10.1136\/jcp.2006.039552.","journal-title":"J Clin Pathol"},{"issue":"5","key":"8070_CR51","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/annonc\/mds614","volume":"24","author":"MA Merok","year":"2013","unstructured":"Merok MA, Ahlquist T, R\u00f8yrvik EC, Tufteland KF, Hektoen M, Sjo OH, et al. Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive norwegian series. Ann Oncol. 2013;24(5):1274\u201382. https:\/\/doi.org\/10.1093\/annonc\/mds614.","journal-title":"Ann Oncol"},{"issue":"1","key":"8070_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/cge.13628","volume":"97","author":"Z Deng","year":"2020","unstructured":"Deng Z, Qin Y, Wang J, Wang G, Lang X, Jiang J, et al. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: a systematic review and meta-analysis. Clin Genet. 2020;97(1):25\u201338. https:\/\/doi.org\/10.1111\/cge.13628.","journal-title":"Clin Genet"},{"issue":"12","key":"8070_CR53","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1245\/s10434-011-1731-2","volume":"18","author":"DJ Sargent","year":"2011","unstructured":"Sargent DJ, Resnick MB, Meyers MO, Goldar-Najafi A, Clancy T, Gill S, et al. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis. Ann Surg Oncol. 2011;18(12):3261\u201370. https:\/\/doi.org\/10.1245\/s10434-011-1731-2.","journal-title":"Ann Surg Oncol"},{"key":"8070_CR54","doi-asserted-by":"publisher","unstructured":"Wang JB, Ma DL, Li JY, Sun QD, Liu YE. Association between expression of DNA mismatch repair genes and clinical features and prognosis of patients with radical resection of colon cancer. Genet Mol Res. 2016;15(3). https:\/\/doi.org\/10.4238\/gmr.15038388.","DOI":"10.4238\/gmr.15038388"},{"issue":"1","key":"8070_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13000-017-0613-8","volume":"12","author":"W Chen","year":"2017","unstructured":"Chen W, Swanson BJ, Frankel WL. Molecular genetics of microsatellite-unstable colorectal cancer for pathologists. Diagn Pathol. 2017;12(1):24. https:\/\/doi.org\/10.1186\/s13000-017-0613-8.","journal-title":"Diagn Pathol"},{"issue":"12","key":"8070_CR56","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/modpathol.2013.101","volume":"26","author":"MD Walsh","year":"2013","unstructured":"Walsh MD, Clendenning M, Williamson E, Pearson SA, Walters RJ, Nagler B, et al. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod Pathol. 2013;26(12):1642\u201356. https:\/\/doi.org\/10.1038\/modpathol.2013.101.","journal-title":"Mod Pathol"},{"issue":"1","key":"8070_CR57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/BF02050301","volume":"36","author":"JB Green","year":"1993","unstructured":"Green JB, Timmcke AE, Mitchell WT, Hicks TC, Gathright JB, Ray JE. Mucinous carcinoma-just another colon cancer? Dis Colon Rectum. 1993;36(1):49\u201354. https:\/\/doi.org\/10.1007\/BF02050301.","journal-title":"Dis Colon Rectum"},{"issue":"11","key":"8070_CR58","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1245\/s10434-013-3169-1","volume":"20","author":"SH Kim","year":"2013","unstructured":"Kim SH, Shin SJ, Lee KY, Kim H, Kim TI, Kang DR, et al. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage iii colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. Ann Surg Oncol. 2013;20(11):3407\u201313. https:\/\/doi.org\/10.1245\/s10434-013-3169-1.","journal-title":"Ann Surg Oncol"},{"key":"8070_CR59","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fmed.2020.00205","volume":"7","author":"Y Huang","year":"2020","unstructured":"Huang Y, Ge K, Fu G, Chu J, Wei W. Mucinous histology might be an indicator for enhanced survival benefit of chemotherapy in stage II colon cancer. Front Med. 2020;7:205. https:\/\/doi.org\/10.3389\/fmed.2020.00205.","journal-title":"Front Med"},{"issue":"4","key":"8070_CR60","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/omi.2010.0053","volume":"14","author":"X Fang","year":"2010","unstructured":"Fang X, Yu W, Li L, Shao J, Zhao N, Chen Q, et al. ChIP-seq and functional analysis of the SOX2 gene in colorectal cancers. Omi A J Integr Biol. 2010;14(4):369\u201384. https:\/\/doi.org\/10.1089\/omi.2010.0053.","journal-title":"Omi A J Integr Biol"},{"issue":"1","key":"8070_CR61","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1186\/1471-2407-11-518","volume":"11","author":"J Neumann","year":"2011","unstructured":"Neumann J, Bahr F, Horst D, Kriegl L, Engel J, Mej\u00edas-Luque R, et al. SOX2 expression correlates with lymph-node metastases and distant spread in right-sided colon cancer. BMC Cancer. 2011;11(1):518. https:\/\/doi.org\/10.1186\/1471-2407-11-518.","journal-title":"BMC Cancer"},{"issue":"58","key":"8070_CR62","doi-asserted-by":"publisher","first-page":"98635","DOI":"10.18632\/oncotarget.21709","volume":"8","author":"J Zheng","year":"2017","unstructured":"Zheng J, Xu L, Pan Y, et al. Sox2 modulates motility and enhances progression of colorectal cancer via the Rho-ROCK signaling pathway. Oncotarget. 2017;8(58):98635\u2013945. https:\/\/doi.org\/10.18632\/oncotarget.21709.","journal-title":"Oncotarget"},{"key":"8070_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/3761535","volume":"3761535","author":"K Song","year":"2020","unstructured":"Song K, Hao J, Ge Z, Chen P. Clinical and survival impact of sex-determining region Y-box 2 in colorectal cancer: an integrated analysis of the immunohistochemical study and bioinformatics analysis. J Oncol. 2020;3761535:1\u201311. https:\/\/doi.org\/10.1155\/2020\/3761535.","journal-title":"J Oncol"},{"issue":"14","key":"8070_CR64","doi-asserted-by":"publisher","first-page":"12763","DOI":"10.18632\/oncotarget.3497","volume":"6","author":"CW Ong","year":"2015","unstructured":"Ong CW, Chong PY, McArt DG, et al. The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers. Oncotarget. 2015;6(14):12763\u201373. https:\/\/doi.org\/10.18632\/oncotarget.3497.","journal-title":"Oncotarget"},{"key":"8070_CR65","doi-asserted-by":"publisher","unstructured":"Takeda K, Mizushima T, Yokoyama Y, et al. Sox2 is associated with cancer stem-like properties in colorectal cancer. Sci Rep. 2018;8(1). https:\/\/doi.org\/10.1038\/s41598-018-36251-0.","DOI":"10.1038\/s41598-018-36251-0"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08070-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-08070-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08070-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T19:06:38Z","timestamp":1617735998000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08070-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8070"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08070-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,6]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of retrospective samples from which informed consent cannot be obtained is authorized for research studies by the Portuguese law - No 12\/2005, article 19(6). Recent samples included in the biobank had written informed consent and the study was approved by the ethics committee of CHSJ (Process n\u00b0 126\u201317).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"359"}}